FGF21 has been a hormone of intense interest for metabolic research due to its broad role in adapting the body’s physiology to nutritional stressors such as fasting, ketogenic diets, and protein restriction. Until now, much of the focus has centered on the hypothalamus and other forebrain regions as primary sites where FGF21 signaling modulates appetite and metabolic rate. However, the current study, spearheaded by Dr. Christopher Morrison and his team, shifts the paradigm by identifying a discrete population of neurons in the hindbrain that directly respond to FGF21.

Through meticulous experimentation using state-of-the-art molecular tracing and neuronal activity mapping techniques, the researchers demonstrated that these hindbrain neurons are not only responsive to FGF21 but are essential mediators of the hormonal signals triggered by dietary protein restriction. When these neurons are activated, they induce coordinated changes in feeding patterns and energy expenditure—processes vital for maintaining systemic energy homeostasis under conditions of limited protein intake.

Importantly, the study dissects the functional dynamics of this circuit, revealing that it is both necessary and sufficient to elicit key metabolic adaptations. Activation of the hindbrain neurons modified food intake quantity and altered macronutrient preference, steering animals toward compensatory dietary behavior. Concomitantly, energy expenditure adjustments were observed, suggesting an integrated control mechanism that recalibrates both consumption and caloric burn in response to nutritional cues relayed by FGF21.

These findings complicate the previously held notion that appetite and energy balance are predominantly managed by higher brain centers. Instead, they highlight an intricate, distributed neuroendocrine network where the hindbrain plays a pivotal, previously underestimated role. This neurological locus functions as a crucial hub that interprets hormonal signals from the periphery and orchestrates systemic metabolic responses.

The implications for treating obesity and associated metabolic syndromes are profound. These conditions often arise from maladaptive energy regulation and impaired signaling pathways between the brain and body. By targeting the hindbrain neurons responsive to FGF21, novel therapeutic strategies might be developed that enhance metabolic flexibility and correct aberrant feeding behaviors. Such precision medicine approaches could surpass the efficacy of current treatments, which often struggle with heterogeneity in patient responses and undesirable side effects.

Moreover, the study underscores that the benefits of FGF21-based therapeutics could be maximized by refining drug delivery to engage specific neural circuits rather than broad systemic exposure. This neurocentric targeting has the potential to minimize off-target effects and optimize metabolic endpoints such as basal metabolic rate and dietary preferences, which have heretofore been overlooked in clinical evaluation frameworks.

Dr. Morrison, co-director of the Neurosignaling Laboratory at Pennington Biomedical, emphasized how this work exemplifies the intimate link between nutrition and brain function. He articulated the concept that the brain continuously monitors dietary inputs and dynamically adjusts physiological outputs to maintain internal balance, a process likened to an evolving dialogue between peripheral organs and central neural systems.

This research was conducted with rigorous support from the National Institutes of Health and underscores the contributions of specialized core facilities at Pennington Biomedical, including the Comparative Biology Core and the Animal Metabolism and Behavior Core. The multidisciplinary team involved experts across neurobiology, metabolism, and endocrinology, who collectively mapped this FGF21-hindbrain axis with remarkable precision.

As the obesity epidemic persists globally, unraveling the molecular and cellular substrates governing energy homeostasis gains ever-greater urgency. The identification of hindbrain neurons as critical nodes in FGF21 signaling pathways offers a fresh conceptual framework for re-imagining how metabolic health can be restored by harnessing the brain’s intrinsic adaptive capabilities.

Looking ahead, ongoing research efforts will focus on delineating the downstream pathways and synaptic partners of these hindbrain neurons, as well as their interactions with other neuroendocrine circuits. Comprehensive understanding of these networks promises to illuminate the complex neurobiology underlying eating behavior regulation and energy dynamics, further informing therapeutic innovation.

This study’s insights extend beyond basic science, positioning FGF21 as not only a metabolic sentinel but also a neuromodulator with critical regulatory influence. By redefining the neural substrates of diet-induced metabolic adaptation, this work propels the field closer to translating molecular discoveries into impactful clinical solutions for metabolic disease.

Subject of Research: Animals

Article Title: FGF21 signals through hindbrain neurons to alter food intake and energy expenditure during dietary protein restriction

News Publication Date: 28-Apr-2026

Web References:

• FGF21 signals through hindbrain neurons (Cell Reports)
• Q&A with Cell Reports on FGF21 research

Image Credits: PBRC/Cell Reports

Keywords: FGF21, hindbrain neurons, food intake, energy expenditure, dietary protein restriction, metabolism, neuroendocrine signaling, obesity, metabolic health, neuroscience

Mitochondria, often described as the powerhouses of cells, perform the essential function of generating adenosine triphosphate (ATP), the cellular energy currency, through oxidative phosphorylation. In skeletal muscle cells, mitochondrial integrity and functionality are paramount for maintaining metabolic health and insulin responsiveness. In patients with T2D, mitochondrial dysfunction is a hallmark characteristic that contributes to impaired glucose uptake and systemic insulin resistance. The Pennington team’s study puts a spotlight on how alterations in mitochondrial dynamics and autophagic quality control are pivotal in this context.

At the heart of mitochondrial quality control lies a cellular process termed mitophagy, a specialized form of autophagy responsible for removing damaged or dysfunctional mitochondria. Efficient mitophagy ensures cellular homeostasis by selectively degrading impaired mitochondria, thus preventing the accumulation of harmful reactive oxygen species (ROS) and metabolic deficits. However, in the muscles of individuals suffering from T2D, mitophagy is compromised, leading to a cascade of metabolic disturbances. The new findings reveal how cells adapt to this impairment by modulating mitochondrial morphology and fragmenting mitochondria to bypass dysfunctional pathways.

Central to this adaptive response is a protein called dynamin-related protein 1 (DRP1), which orchestrates mitochondrial fission. DRP1 activity is found to be hyperactivated in T2D, resulting in excessive mitochondrial fragmentation. While mitochondrial fission is generally a normal physiological process that aids mitochondrial turnover and quality control, its hyperactivation reflects a compensatory mechanism that attempts to sustain mitochondrial function when mitophagy pathways are defective. This nuanced interplay between mitochondrial fission and mitophagy depicts a complex cellular response to metabolic stress.

Moreover, the study explores the role of deubiquitinating enzymes, which are emerging as critical regulators of mitochondrial dynamics and insulin sensitivity. DUBs are specialized proteases that remove ubiquitin molecules from proteins, influencing their stability and function. In the context of skeletal muscle in T2D patients, certain DUBs interfere with the ubiquitin-mediated signaling required for effective mitophagy. This interference further impairs the removal of damaged mitochondria, compounding deficits in muscle insulin sensitivity and energy metabolism.

Through detailed biochemical and cellular analyses, the research team led by Dr. John Kirwan demonstrated that the aberrant activity of DUBs disrupts mitochondrial quality control mechanisms, precipitating mitochondrial dysfunction and insulin resistance. This revelation is crucial because it links enzymatic regulation at the post-translational level directly with the metabolic derangements characteristic of T2D. It suggests that targeting DUBs could represent a novel therapeutic strategy to restore mitochondrial fidelity and improve insulin action in skeletal muscle.

Importantly, the researchers found that despite impaired mitophagy, skeletal muscle cells employ mitochondrial fragmentation as an alternative adaptive strategy to maintain mitochondrial quality. This “backup plan” involves increasing mitochondrial fission to segregate damaged mitochondria, thereby allowing their selective degradation or functional isolation. While this adaptation delays the detrimental metabolic consequences of mitochondrial dysfunction, it is ultimately insufficient to prevent the progression of insulin resistance, underscoring the need for intervention at the molecular level.

The clinical implication of these findings cannot be overstated. Insulin resistance in skeletal muscle is a primary defect in the majority of individuals with T2D and represents a major barrier to effective glycemic control. By delineating the molecular players involved in mitochondrial dysregulation, such as DRP1 and DUBs, this study maps out the intricate signaling networks that could be exploited to reverse or alleviate muscle insulin resistance. It also provides a foundation for future research aimed at developing pharmacological agents to modulate mitochondrial dynamics favorably.

Dr. Kirwan reflects on the significance of their findings: “Our investigations reveal that when the classical mitochondrial cleanup pathways fail, skeletal muscle cells adaptively increase mitochondrial fragmentation to cope with metabolic challenges. This discovery highlights the delicate balance between mitochondrial fission and quality control in diabetic muscle and offers new avenues for therapeutic targeting to restore metabolic health.” His team’s work exemplifies the cutting-edge research emerging from Pennington Biomedical, a leader in metabolic disease science.

The study was made possible by the collaborative efforts of scientists within Pennington’s Integrated Physiology and Molecular Medicine Laboratory, showcasing state-of-the-art techniques in molecular biology, biochemistry, and physiology. Additionally, the research benefited from core facility resources supported by several NIH grants and institutional partnerships, emphasizing the importance of sustained funding and interdisciplinary collaboration in advancing biomedical knowledge.

Given the rising global prevalence of T2D and its associated complications, understanding the cellular underpinnings of insulin resistance remains a research priority with profound public health implications. The identification of DUB antagonists as potential modulators of mitochondrial quality control represents a promising therapeutic horizon. Further studies evaluating the safety, efficacy, and clinical applicability of such agents are warranted to translate these insights into patient care.

In summary, this pivotal research sheds light on the critical nexus between mitochondrial dynamics, quality control, and insulin sensitivity in skeletal muscle, offering a compelling narrative of how cells strive to maintain metabolic function amidst diabetic stress. By unraveling the molecular determinants of mitochondrial integrity disruption, the study paves the way for novel interventions in the management of Type 2 Diabetes and related metabolic disorders.

Subject of Research: People

Article Title: Deubiquitinating Enzymes Regulate Skeletal Muscle Mitochondrial Quality Control and Insulin Sensitivity in Patients With Type 2 Diabetes

News Publication Date: 4-Mar-2025

Web References:
https://www.pbrc.edu/
https://onlinelibrary.wiley.com/doi/10.1002/jcsm.13763

References:
John Kirwan et al., “Deubiquitinating Enzymes Regulate Skeletal Muscle Mitochondrial Quality Control and Insulin Sensitivity in Patients with Type 2 Diabetes,” Journal of Cachexia, Sarcopenia and Muscle, 2025.

Image Credits: Journal of Cachexia, Sarcopenia and Muscle

Keywords: Diabetes, Type 2 diabetes, Insulin, Obesity, Cell biology, Cells, Cellular physiology, Cell structure, Mitochondria, Health and medicine, Clinical medicine, Human health